Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

A sepsis-predicting diagnostic for prioritized patient care in the ICU

FY 2025-26

Summary
Sepsis is the number-one cause of death in the world. Death occurs in under 12 hours. Sepsis has no cure. During the pandemic, the majority of deaths were from COVID-induced sepsis. Hospitals became overwhelmed. In less fortunate countries, this is always the case. To save the most lives possible, equitable resource allocation is critical. The most severe cases must be prioritized. Unfortunately, this is impossible because sepsis is difficult to diagnose and progresses so quickly. It is clear: hospitals need a cheap, fast, and readily available sepsis diagnostic that can detect sepsis early and predict severity for efficient patient triaging and resource prioritization. Together with our collaborators at St. Michael’s Hospital (SMH) and Sepset Inc., using machine learning to mine sepsis blood samples, we have discovered 8 mRNA biomarkers. Based on how much of each biomarker is in a patient’s blood, we can predict sepsis severity and patient outcome. To automate sample processing at the point-of-care, in collaboration with National Research Council Canada, we have engineered a novel lab-on-a-chip (LOC) platform: the PowerBlade. To bridge our novel biomarkers and LOC, providing a usable technology, having a real-world impact on sepsis patients and the healthcare system, here, I propose a novel CRISPR diagnostic for fast, cheap, on-site RNA-quantification. Through diagnostic development, clinical validation, LOC incorporation, and a real-world demonstration with patients in the ICU, I will bring our sepsis biomarkers from the lab to patients’ bedsides. My diagnostic will have an immediate real-world impact: doctors and nurses will be able to predict sepsis outcomes and triage patients accordingly. The most severe cases will finally receive the priority they deserve.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572809
Name
Kelly Paul F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A sepsis-predicting diagnostic for prioritized patient care in the ICU
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Crispr; Decentralized Healthcare; Diagnostics; Intensive Care; Lab-On-A-Chip; Medical Equity; Microfluidics; Point-Of-Care; Sepsis; Septic Shock
Abstract
Sepsis is the number-one cause of death in the world. Death occurs in under 12 hours. Sepsis has no cure. During the pandemic, the majority of deaths were from COVID-induced sepsis. Hospitals became overwhelmed. In less fortunate countries, this is always the case. To save the most lives possible, equitable resource allocation is critical. The most severe cases must be prioritized. Unfortunately, this is impossible because sepsis is difficult to diagnose and progresses so quickly. It is clear: hospitals need a cheap, fast, and readily available sepsis diagnostic that can detect sepsis early and predict severity for efficient patient triaging and resource prioritization. Together with our collaborators at St. Michael’s Hospital (SMH) and Sepset Inc., using machine learning to mine sepsis blood samples, we have discovered 8 mRNA biomarkers. Based on how much of each biomarker is in a patient’s blood, we can predict sepsis severity and patient outcome. To automate sample processing at the point-of-care, in collaboration with National Research Council Canada, we have engineered a novel lab-on-a-chip (LOC) platform: the PowerBlade. To bridge our novel biomarkers and LOC, providing a usable technology, having a real-world impact on sepsis patients and the healthcare system, here, I propose a novel CRISPR diagnostic for fast, cheap, on-site RNA-quantification. Through diagnostic development, clinical validation, LOC incorporation, and a real-world demonstration with patients in the ICU, I will bring our sepsis biomarkers from the lab to patients’ bedsides. My diagnostic will have an immediate real-world impact: doctors and nurses will be able to predict sepsis outcomes and triage patients accordingly. The most severe cases will finally receive the priority they deserve.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kelly, Paul F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~